Drug Trial Radar · NCT06500637
TB006 for Autism Spectrum Disorder
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Aug 3, 2024
Primary completion
Dec 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Rossignol Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Autism Discovery and Treatment Foundation
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.
Conditions
- Autism Spectrum Disorder
Interventions
TB006Drug
TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Childhood Autism Rating Scores (CARS)Time frame: Baseline, Week 8 and Week 14
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Rossignol Medical Center
Phoenix, Arizona · Recruiting
Rossignol Medical Center
Aliso Viejo, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.